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ence measures and utility values for individual treat-
ment attributes. Differential toxicity attributes, that were
patient relevant and clinically signiﬁcant, were identiﬁed
from head-to-head trial data. Attributes identiﬁed were:
alopecia, weight loss, mucositis, diarrhoea, and febrile
neutropenia/neutropenic sepsis. Fourteen oncologists and
16 oncology nurses served as patient proxies given the
sensitive nature and ethical difﬁculties associated with the
patient population. Respondents considered an orthogo-
nally designed series of pair-wise choice scenarios repre-
senting incidence levels for individual toxicity attributes
(treatment features) with trade-offs in life-expectancy. 
A logistic regression was utilised to analyse the stated 
scenario pair preferences against the individual attribute
levels. Potential confounders were analysed. RESULTS:
Survey results indicate a strong preference for GC treat-
ment and a clear willingness-to-trade-time for tolerability
beneﬁts. Analysis of strength of preference for individual
attributes shows strong support for treatment features
that impact directly on QoL. CONCLUSIONS: UK
respondents displayed a clear preference for GC treat-
ment with superior toxicity offering a highly valued
health related QoL gain. These results provide encour-
agement for further exploration, possibly by extension to
the European setting. Discrete choice conjoint analysis is




IS THERE DIFFERENCE BETWEEN
GEMCITABINE BASED NSCLC TREATMENT AND
OTHER PLATINUM BASED COMBINATIONS FOR
RESPONSE RATES AND TOXICITY?
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OBJECTIVE: This analysis attempts to highlight the 
differences in response rates and toxicity between 
Gemcitabine combined with a platinum-based therapy
and other combinations of platinum-based chemother-
apy, in the treatment of non-small-cell lung cancer
(NSCLC). METHODS: This pooled analysis used
summary statistics from clinical trials published up to
December 2001. The analysis pooled odds ratios (OR)
and associated conﬁdence intervals (CI) using a ﬁxed-
effects model. The efﬁcacy outcomes considered are
responses (both partial and complete) and progressive
disease. Grade 3 and 4 toxicities are considered using the
WHO criteria for the following adverse events: alopecia,
nausea and vomiting, anaemia, neutropenia, thrombocy-
topenia and neuropathy. RESULTS: Patients receiving
Gemcitabine combined with a platinum therapy are more
likely to experience a response to treatment than patients
receiving other platinum based combinations. The OR for
complete and partial responses is 2.68, (CI 1.53–4.67)
and is 0.44 for progressive disease (CI 0.32–0.59). Gem-
citabine patients experienced fewer cases of alopecia 
(OR 0.15, CI 0.10–0.22) and neutropenia (OR 0.6, CI
0.47–0.77). In contrast, Gemcitabine patients experi-
enced a greater number of grade 3 or 4 anaemia (OR
1.92, CI 1.41–2.61) and thrombocytopenia (OR 6.76 CI
4.95–9.23) incidences. For neuropathy and nausea and
vomiting there was no evidence for any of the chemother-
apies having fewer patients experiencing toxicities. CON-
CLUSIONS: The implications of this analysis at the
patient level is that if response is of primary importance,
then on a purely clinical basis Gemcitabine should be the
treatment of choice. Gemzar based chemotherapy had a
higher number of responses and fewer adverse events 
for alopecia and neutropenia. To validate these results, a
meta-analysis should be conducted with stratiﬁcation for
key variables using patient level data.
PCN21
CANCER CHEMOTHERAPY AT HOME:
FEASIBILITY, PATIENT OUTCOMES,AND
HEALTHCARE SYSTEM IMPLICATIONS
Boothroyd LJ1, Lehoux P2
1Agence d’Evaluation des Technologies et des Modes
d’Intervention en Sante, Montreal, QC, Canada; 2University of
Montreal, Montreal, QC, Canada
OBJECTIVES: At the Quebec Health Technology Assess-
ment Agency (AETMIS) in Canada we assessed whether
home chemotherapy for cancer was effective, safe, and
satisfactory to patients, and examined the cost, organi-
zational, and ethical implications, in order to make 
policy recommendations. METHODS: We carried out 
a systematic review of the scientiﬁc literature using 
the PubMed (MEDLINE 1980–present) and CancerLit
(1975–present) bibliographic databases. We supple-
mented this review with 16 semi-structured interviews
with service providers, including oncology nurses, physi-
cians, and home care coordinators, in 2 provinces 
with different organizational structures for cancer care
(Quebec and Ontario). RESULTS: Clinical effectiveness
of home cancer chemotherapy appears similar to that 
in non-home settings. Home treatment can be delivered
safely if patients are carefully selected and trained. Patient
eligibility criteria relate to learning capability, suitability
of the home environment, and geographic accessibility.
Improvements in patient quality of life at home have not
been well documented in the literature. Patient preference
and satisfaction with home therapy is supported,
although mostly among self-selected groups. Cost studies
show that home chemotherapy is less expensive than
inpatient treatment from a hospital perspective. When
home treatment is used as a substitute for outpatient
therapy, the result tends to be a cost shifting from hospi-
tals to home care organizations. Effects on costs to
patients/families require more study. Interviews with
service providers showed variable delivery, with greater
patient load capacity and uniformity of services where
hospital oncology departments or regionalized centres 
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of expertise have organized, collaborative links with 
community home care services and sufﬁcient resources.
CONCLUSIONS: Home chemotherapy requires a well-
integrated multidisciplinary team of health professionals
in partnership with selected patients and their informal
caregivers. Our study shows the need for regionalized
approaches within centralized standard setting and
funding, increased resources and support for program




PATIENTS TO COMBINED GLIBENCLAMIDE
AND METFORMIN (GLUCOVANCE) WHEN
POORLY CONTROLLED WITH METFORMIN
MONOTHERAPY:THE FRENCH PERSPECTIVE
Roze S1, Palmer AJ1, Cabrières L2, Comte S2
1CORE Center for Outcomes Research, Basel, Switzerland;
2Lipha S.A.S, Lyon, France
OBJECTIVES: Poor glycaemic control is associated with
increased risk of micro- and macro-vascular disease in
type 2 diabetes (T2D) patients. Switching patients from
metformin to Glucovance (combined glibenclamide/
metformin) leads to improved glycaemic control in pre-
viously poorly controlled patients. No long-term studies
have been performed that compare complication rates,
mortality, and long-term costs in patients switched from
metformin to Glucovance. A method was sought to link
the effects on glycaemic control of switching from met-
formin to Glucovance to long-term complication rates
and associated costs. METHODS: A validated model was
used to quantify the improvements in life expectancy
(LE), the changes in total lifetime costs (TC) associated
with the improved glycaemic control seen with switching
patients from metformin to Glucovance. Standard
Markov modelling was used to describe the long-term
incidence and progression of diabetes-related complica-
tions (angina, MI, stroke, heart failure, peripheral vascu-
lar disease, neuropathy, foot ulcer, amputation, renal
disease, and eye disease). Probabilities of complications
and HbA1c-dependent adjustments were derived from
published studies. Switching from metformin to Glucov-
ance lead to a 1% point improvement in HbA1c. Direct
costs of diabetes complications and treatment with either
metformin or Glucovance were projected over patients’
lifetimes (discounted 5% p.a.). Costs of complications
were retrieved from published sources. A French third
party payer perspective was taken. A typical type 2 
diabetes cohort (baseline age of 59) was simulated over a
30 years period. Exstensive sensitivity analysis was 
performed. RESULTS: Improved glycaemic control 
after switching from metformin to Glucovance lead to
decreased incidence and progression of diabetes-related
complications, with an increase in LE of 0.80 years, and
reduction in TC/patient of €2,050. CONCLUSIONS:
Switching from metformin to Glucovance is dominant to
maintaining patients on MET monotherapy with poor
control. Further long-term clinical studies with economic
data collection are required to conﬁrm these results.
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OBJECTIVES: To estimate the cost-effectiveness of
glycemic control with pioglitazone hydrochloride com-
pared to conventional treatment for Japanese patients
with Type II diabetes. METHODS: This study used the
Japanese Diabetes Risk Simulation Software to estimate
the lifetime cost per life-year or quality-adjusted life year
(QALY). The hypothetical cohort was comprised of 1000
individuals living in Japan, aged 50 years, who were
newly diagnosed as having Type II diabetes without
retinopathy, nephropathy complications or history of
coronary heart disease (CHD). Clinical effectiveness data
were taken from the results of clinical trials conducted in
Japan. Cost data were based on the fee schedule used for
hospital outpatients in 2000. Costs (in 2000, Japanese
yen), life expectancy and QALYs were discounted at 3%
per annum. RESULTS: Glycemic control with pioglita-
zone hydrochloride reduced the cumulative incidence of
blindness, dialysis and CHD by 22.2%, 12.2% and
7.9%, respectively. As a result, it produced a net saving
of 390,000 yen per patient over the lifetime despite the
additional annual cost of 70,000 yen for pharmacother-
apy. Increased life expectancy was 0.61 years, and 0.68
QALYs was gained. CONCLUSIONS: Glycemic control
with pioglitazone hydrochloride reduces costs and
improves health outcomes relative to conventional treat-
ment in patients with Type II diabetes in Japanese clini-
cal settings.
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OBJECTIVES: In the Diabetes Prevention Program
(DPP), overweight patients with impaired glucose toler-
ance randomized to either intensive lifestyle changes
(ILC) or metformin (MET) reduced their risk of develop-
